InVivo Therapeutics enrols Keck Hospital patient into INSPIRE study

118
Invivo Therapeutics’ Neuro-spinal scaffold

A new patient has been enrolled into InVivo Therapeutics’ INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Keck Hospital of University of Southern California, Los Angeles, USA.

Patrick Hsieh, principal investigator at the site performed the implantation approximately 82 hours after the injury occurred.

“The implantation of the neuro-spinal scaffold went smoothly and the patient is recovering well,” Hsieh says. “I have now implanted two patients, and it is rewarding to be able to give spinal cord injury patients hope with novel investigational products that were not available previously. I look forward to following and communicating the patient’s progress.”

Mark Perrin, InVivo’s chief executive officer and chairman, says, “We now have 12 patients enrolled and in follow-up in INSPIRE…this enrolment marks another significant step toward completing enrolment in the INSPIRE study.”

In addition, the company has announced that it plans to initiate its first study investigating cervical spinal cord injury in Canada over the coming months.